Releaf
Releaf · page 3
- Opinion
From Specialists to GPs: Releaf on Expanding Access to Medical Cannabis Training in the UK
Business of Cannabis recently sat down with Releaf’s Chief Operating Officer, Graham Woodward, a trained psychiatric nurse and former clinical director and CQC Specialist Advisor, to discuss the impact of the lack of access to training how clinics such as Releaf are working to change it.
- Opinion
Incumbent UK Providers Are the ‘Root Cause of the Sector’s Stagnation Since the Legalisation of Medical Cannabis in 2018′
Since the UK legalisation of CBPMs in 2018, the sector has faced slow adoption due to ineffective patient outreach, inconsistent supply chains and variable quality control from other providers.
- Medical
The Untapped Potential: How UK Medical Cannabis Prescriptions are Growing but Missing Millions
Approaching the sixth anniversary of the legalisation of medical cannabis in the UK, private prescriptions are on the rise, but broader awareness among professionals and the public still lags behind.
- Press releases
Somai Pharmaceuticals Announces Partnership with Releaf Clinic
SOMAÍ Pharmaceuticals is proud to announce a strategic partnership with Releaf, the UK’s fastest-growing medical cannabis clinic, to bring innovative cannabis-based treatments to Releaf’s rapidly expanding patient base.
- Data & Analysis
Lack of Awareness Leaves Millions Without Medical Cannabis Benefits
Over half of the UK’s population could benefit from medical cannabis, but the lack of awareness means millions of potential patients continue to turn to other treatments.
- Medical
UK GP’s Critical Role in Prescribing Medical Cannabis
Written for Business of Cannabis by Releaf. General Practitioners (GPs) are on the frontline of healthcare in the UK, and represent the primary touchpoint for patients hoping to get treatment.
- Medical
Milestone for UK Medical Cannabis as Glass Pharms’ First Domestically Grown Medical Cannabis Arrives
Medical cannabis cultivator Glass Pharms has officially delivered its first crop to the first UK-based clinic, marking the first time since medical cannabis was legalised that domestically grown product has been made available to patients.
- Sponsored
Unlocking the Potential: UK’s Evolving Landscape of Medical Cannabis Research
Written for Business of Cannabis by Releaf. The UK moved to legalise medical cannabis in 2018, but while the market has grown rapidly over the last five years, seeing the UK become the second largest market in Europe, barriers remain that continue to prevent the industry from reaching its full potential.
- CBD Market
Astrasana Holding AG Successfully Completes Majority Acquisition of Releaf for Pets, Europe’s Premier Approved CBD Veterinary Product Line
Astrasana Holding AG is pleased to announce the successful completion of the majority acquisition of Releaf for Pets, marking a significant milestone for Europe’s foremost approved CBD veterinary product line.
- Adult-Use
What’s In Store For The European Cannabis Industry In 2023? (Part 2)
You can read Part 1 of our 2023 predictions here. Enexis AB According to the cannabis investment firm Enexis, economic pressures will mean capital available for the European cannabis industry will be ‘scarce’ in the first half of 2023; however, it predicts that this will begin to ‘rebound thereafter’.
